🍪 Cookies

We use cookies to store, access and process personal data to give you the best online experience. By clicking Accept Cookies you consent to storing all cookies and ensure best website performance. You can modify cookie preferences or withdraw consent by clicking Cookie Settings. To find out more about cookies and purposes, read our Cookie Policy and Privacy Notice.

Cookies settings


Cookie Control

What are cookies?

Cookies are small text files that enable us, and our service provides to uniquely identify your browser or device. Cookies normally work by assigning a unique number to your device and are stored on your browser by the websites that you visit as well as third-party service providers for those website. By the term cookies other technologies as SDKs, pixels and local storage are to be considered.


If Enabled

We may recognize you as a customer which enables customized services, content and advertising, services effectiveness and device recognition for enhanced security
We may improve your experience based on your previous session
We can keep track of your preferences and personalize services
We can improve the performance of Website.


If Disabled

We won't be able to remember your previous sessions, that won't allow us to tailor the website according to your preferences
Some features might not be available and user experience reduced without cookies


Strictly necessary means that essential functions of the Website can not be provided without using them. Because these cookies are essential for the properly working and secure of Website features and services, you cannot opt-out of using these technologies. You can still block them within your browser, but it might cause the disfunction of basic website features.

  • Setting privacy preferences
  • Secure log in
  • Secure connection during the usage of services
  • Filling forms

Analytics and performance tracking technologies to analyze how you use the Website.

  • Most viewed pages
  • Interaction with content
  • Error analysis
  • Testing and Measuring various design effectivity

The Website may use third-party advertising and marketing technologies.

  • Promote our services on other platforms and websites
  • Measure the effectiveness of our campaigns

ozios_close
Mobile app

Download our mobile application and trade without restrictions. You can have all your investments in your pocket and under control wherever you go.

Moderna vs. Pfizer – Who’s Winning?

After COVID-19 infected the globe, a slew of companies raced to create the ultimate vaccine which would promise extraordinary returns. Those which successfully tackled the epidemic via vaccines & pills were Pfizer, Moderna, Johnson & Johnson, Sputnik, among others.

After COVID-19 infected the globe, a slew of companies raced to create the ultimate vaccine which would promise extraordinary returns. Those which successfully tackled the epidemic via vaccines & pills were Pfizer, Moderna, Johnson & Johnson, Sputnik, among others.

In the USA, Pfizer is regarded as a pioneer in the realm of pharmaceuticals, founded all the way back in 1849 by two German immigrants as a fine chemicals business. Over the years, Pfizer has evolved & capitalized on the emerging trends in the pharma & health sectors, with its brands including the immensely-popular Advil, Lyrica and Viagra drugs.

Decade after decade, pharmaceutical companies have come & go, and one which marked a dent in the sphere of health would be Moderna. It’s an American pharmaceutical and biotechnology company which predominantly centers around therapeutics and vaccines, and its recent success related to the epidemic were paramount.

Both Pfizer and Moderna formulated, produced & delivered hundreds of thousands of their accredited COVID-19 remedies, but which of the two has been more successful recently?

Recent Performance

In the most recent quarter ended July, Pfizer excelled in every financial metric out there:

  •    Revenue: $27.74 billion

  •    Net income: $9.91 billion

  •    Diluted earnings per share: $1.73

The pharma behemoth enjoyed a tremendous period. Revenue grew by 47% on a year-to-year basis, trumping Wall Street expectations by a significant margin. Net income of $9.91 billion represented a 78% jump from the same time a year ago.

Its vaccine, coined Paxlovid, is regarded as the main moneymaker, bringing in $8.8 billion in revenue in the second quarter of this fiscal year. As new waves of the infamous COVID virus emerged across China, and with many individuals opting in for second & third doses of Paxlovid, Pfizer was swimming in prosperity.

Looking into Moderna, its recent performances have also been quite impressive:

  • Revenue: $4.7 billion

  • Net income: $2.2 billion

  • Adjusted earnings per share: $5.24

The optimistic figures were predominantly driven by the surge in COVID-19 vaccine sales, yet, it remains to be the firm’s only product which is available commercially. However, not everything is very bright for Moderna.

The company’s costs have risen to $1.4 billion, or from a different perspective, it ate up 30% of the revenue generated from its trusted vaccine. This is because of significant reductions in the deliveries of its vaccine to both developed and poorer nations.

1_pfizer

Performance of Pfizer, Inc., stock over 5 years. Source: tradingview.com

Looking into the Pfizer stock (NYSE: PFE) from a technical lens, it can be seen that the stock is moving in a negative short-term and long-term trajectory.[1]

Priced at nearly $43 apiece, the stock hovers near 52-week lows and is trading between support levels near $42, and two resistance levels by $45 and $50.

The Pfizer stock has been decayed in 2022 to say the least, losing a quarter of its value throughout the year amid global uncertainty caused by macroeconomic conundrums and surging investor caution.

2_moderna

Performance of Moderna, Inc., stock over 5 years. Source: tradingview.com

On the other side of the spectrum, Moderna stock (NASDAQ: MRNA) also exhibits a very negative long-term trend, but the short-term trajectory looks promising.[2]

The liquid Moderna stock with a price-tag of nearly $134 is trading above a support level of $117, and may perhaps break the $134 barrier and potentially the $183 barrier in the coming month.

While the MRNA stock witnessed its worst year so far, losing nearly half of its value, the future looks positive.[3]

Expectations of Pfizer & Moderna Stock

Both stocks of Pfizer and Moderna are highly regarded in the eyes of analysts as the stocks of the future. Based on current performances and taking into consideration the future endeavors of each firm, the expectations are as follows:

- Pfizer

o   High: $76

o   Average: $55

o   Low: $44

Moderna

o   High: $304

o   Average: $202

o   Low: $77  [4]

As seen, much is expected from Pfizer and Moderna, but Moderna has the edge of the other, despite the credibility of Pfizer and its long history of success.

Moderna is expected to grow exponentially despite the dauting market conditions of today, and it may be a good time for stock purchase.[5]

Adam Austera, analyst of Ozios

 

[1,2,3,4,5] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or based on the current economic environment which is subject to change. Such statements are not guaranteeing of future performance. They involve risks and other uncertainties which are difficult to predict. Results could differ materially from those expressed or implied in any forward-looking statements.

Disclaimer:

The material herein is considered as marketing communication under the relevant laws and regulations, and as such is not a subject to any prohibition on dealing ahead of the dissemination of investment research. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and should not be construed as containing investment advice, or an investment recommendation, or an offer of or solicitation for any transactions in financial instruments. The published content is intended for educational/informational purposes only. It does not take into account readers’ financial situation, personal experience or investment objectives. APME FX Trading Europe Ltd makes no representation that the information provided is accurate, current or complete; and therefore, assumes no liability for any losses arising from investments based on the supplied content. The past performance is not a guarantee of future results.

Is It the Right Time to Invest in Stocks?

After COVID-19 infected the globe, a slew of companies raced to create the ultimate vaccine which would promise extraordinary returns. Those which successfully tackled the epidemic via vaccines & pills...

Development of major vaccine suppliers - Pfizer, BioNTech, Moderna

After COVID-19 infected the globe, a slew of companies raced to create the ultimate vaccine which would promise extraordinary returns. Those which successfully tackled the epidemic via vaccines & pills...

War, Inflation, Recession. How are Major Currencies Performing in 2022?

After COVID-19 infected the globe, a slew of companies raced to create the ultimate vaccine which would promise extraordinary returns. Those which successfully tackled the epidemic via vaccines & pills...
We are also available at +357 25 054 734
© 2022 APME FX TRADING EUROPE LTD

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65.38% of retail investor' accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Read our Risk Disclosures.